<DOC>
	<DOCNO>NCT00943579</DOCNO>
	<brief_summary>This open-label extension study available subject complete earlier double-blind , placebo-controlled study sapropterin child autism . During protocol , subject receive brand-name Kuvan 20 mg/kg/day 16 week ; subject complete first 16 week option continue Kuvan dose 90 day last subject complete first 16 week protocol . The purpose study primarily gather additional information safety efficacy population .</brief_summary>
	<brief_title>Open-Label Extension Study Kuvan Autism</brief_title>
	<detailed_description>This open-label extension study available subject complete earlier double-blind , placebo-controlled study sapropterin child autism . During protocol , subject receive brand-name Kuvan 20 mg/kg/day 16 week ; subject complete first 16 week option continue Kuvan dose 90 day last subject complete first 16 week protocol . The purpose study primarily gather additional information safety efficacy population .</detailed_description>
	<mesh_term>Autistic Disorder</mesh_term>
	<mesh_term>Verapamil</mesh_term>
	<criteria>All subject must complete earlier trial , CHC 0901 ( NCT00850070 ) Parents must willing able sign inform consent Child fail complete CHC 0901 ( NCT00850070 )</criteria>
	<gender>All</gender>
	<minimum_age>3 Years</minimum_age>
	<maximum_age>6 Years</maximum_age>
	<verification_date>July 2013</verification_date>
	<keyword>autism</keyword>
	<keyword>autistic disorder</keyword>
	<keyword>tetrahydrobiopterin</keyword>
	<keyword>sapropterin</keyword>
	<keyword>treatment</keyword>
</DOC>